|会社名||JPMorgan Chase_Co （JPM ＪＰモルガン・チェ―ス）|
|概要||事業概要 JPモルガン・チェース(JPMorgan Chase_Co.)は金融持株会社である。同社は投資銀行事業、融資サービスの提供に従事する。同社は4つの事業区分と企業事業により構成される。消費者・コミュニティ・バンキング事業は銀行支店、現金自動預払機（ATM）、オンライン、モバイルと電話バンキングを通じて、消費者・企業にサービスを提供する。企業・投資銀行事業は企業、投資家、金融機関、政府と地方自治体に投資銀行業務、マーケット・メイキング、プライム・ブローカレッジ、トレジャリーと証券商品・サービスを提供する銀行業務と市場・投資家サービスを含む。商業銀行事業は貸出、トレジャリー・サービス、投資銀行業務、資産管理を含む金融ソリューションを提供する。資産運用事業は投資・資産管理を含む。 JPモルガン・チェ―ス・アンド・カンパニ―は米国の大手金融持株会社。JPモルガン・チェ―ス・バンクは米国23州で銀行業務に従事。チェ―ス・バンクUSAはクレジットカ―ド発行を手掛ける。非銀行系のJPモルガン・セキュリティ―ズは投資銀行、債券・株式業務を行う。米国外の約60カ国において金融事業を展開する。本社はニューヨーク。 JPMorgan Chase & Co. is a financial holding company. It provides financial and investment banking services. The firm offers a range of investment banking products and services in all capital markets, including advising on corporate strategy and structure, capital raising in equity and debt markets, risk management, market making in cash securities and derivative instruments, and brokerage and research. It operates through the following segments: Consumer and Community Banking, Corporate and Investment Bank, Commercial Banking and Asset and Wealth Management. The Consumer and Community Banking segment serves consumers and businesses through personal service at bank branches and through automated teller machine, online, mobile, and telephone banking. The Corporate and Investment Bank segment offers a suite of investment banking, market-making, prime brokerage, and treasury and securities products and services to a global client base of corporations, investors, financial institutions, government and municipal entities. The Commercial Banking segment delivers services to U.S. and its multinational clients, including corporations, municipalities, financial institutions, and non profit entities. It also provides financing to real estate investors and owners as well as financial solutions, including lending, treasury services, investment banking, and asset management. The Asset and Wealth Management segment provides asset and wealth management services. The company was founded in 1968 and is headquartered in New York, NY.|
|本社所在地||270 Park Avenue New York NY 10017 USA|
|代表者氏名||James L. Dimon|
|代表者役職名||Chairman of the Board Chief Executive Officer|
|決算概要||決算概要 BRIEF: For the fiscal year ended 31 December 2018 JPMorgan Chase_Co. interest income increased 20% to $77.44B. Net interest income after loan loss provision increased 12% to $50.19B. Net income applicable to common stockholders excluding extraordinary items increased 26% to $30.71B. Net interest income after loan loss provision reflects Consumer_Business Banking segment increase of 19% to $31.07B Commercial Banking segment increase of 4% to $6.59B.|
Outlook “bright” for hedge funds as industry seizes on surging volatility, JP Morgan Asset Management officials say 2020/07/31 12:37:57 Hedgeweek
Outlook “bright” for hedge funds as industry seizes on surging volatility, JP Morgan Asset Management officials say Submitted By Hugh Leask | 31/07/2020 - 1:37pm The immediate outlook for hedge funds is “very bright”, with elevated volatility at an “optimal” level for macro and relative value strategies in particular, JP Morgan Asset Management’s alternatives team said this week. Jamie Kramer, managing director and head of the Alternatives Solutions Group at JP Morgan Asset Management, said many hedge funds were able to insulate investors’ portfolios during the Q1 market shock before taking advantage of rising markets during Q2’s rally. That showing is now piquing investors’ interest, following a sustained period of allocator aversion in recent years. “Facing a decade of headwinds with low interest rates, low dispersion, [hedge funds] now really are in this goldilocks scenario of being able to protect-and-participate,” Kramer said. In a deep-dive webinar discussion on Thursday, private market experts at JP Morgan Asset Management explored the role of various alternative asset classes in portfolio diversification, against the current market backdrop of low bond yields and Covid-19 uncertainty.
Stocks making the biggest moves midday: UPS, Qualcomm, Valero, JPMorgan & more 2020/07/30 16:45:51 CNBC
Take a look at the companies making headlines in midday trading.
JPMorgan says upside capped for EUR/USD due to long positions approaching high levels 2020/07/30 03:40:50 Forexlive
You might recall yesterday JPM the only looking for gold to top out: one of the few Same of the euro, this (in summary) from an overnight piece: - Systematic and discretionary currency traders have built long euro positions By Eamonn Sheridan
Here Is The Strategy Of The Best Performing Hedge Fund Of 2020 2020/07/29 23:05:11 Zero Hedge
Here Is The Strategy Of The Best Performing Hedge Fund Of 2020 Tyler Durden Wed, 07/29/2020 - 19:05 Sure, there are probably a handful of hedge funds who have generated even higher returns, but for the purpose of this post we are going off the latest HSBC hedge fund weekly report, according to which Boaz Weinstein's Saba Capital is the best performing hedge fund of 2020 with a staggering 90% YTD return. But how is the former Deutsche Bank prop trader making a killing when most of his hedge fund peers are struggling to post a positive return for 2020, let alone beat the S&P500? Conveniently, we have the answer courtesy of a Bloomberg profile digging deep into Weinstein's current living conditions, which just incidentally also happens to discuss his latest - and perhaps greatest - trading strategy. Bloomberg starts off by chronicling Weinstein's current living conditions which in this time of pervasive coronavirus lockdowns, are whimsical, even by a hedge fund manager's standards: Weinstein has repaired to his gated estate in Sagaponack, replete with tennis court, pool and a Vegas-style card room.
Front Lines Against Coronavirus: Gilead, Moderna Prepare To Update Investors 2020/07/29 20:28:34 Benzinga
Ahead of earnings from two of the most closely watched biotechs— Moderna Inc (NASDAQ: MRNA ) and Gilead Sciences, Inc. (NASDAQ: GILD )—one thing seems pretty certain: Investors are likely to care much less than normal about Q2 financial numbers from either. Arguably, both companies could report their worst quarterly earnings and revenue ever and it wouldn’t make as large a dent as you may think. Instead, investors really want to hear about their progress on a coronavirus treatment (GILD) and a coronavirus vaccine (MRNA). “I don’t think MRNA’s earnings or earnings commentary will matter much,” said Kevin Huang, senior equity research analyst at CFRA, an independent investment research firm.” Investors should be focused on clinical trial results and news related to competition.” Any positive news for either firm could end up saying a lot more about where their shares (and maybe the markets) go than anything in their “schedules”—those endless sheets of numbers that go into the back of an earnings press release.